AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada
View the full release here: https://www.businesswire.com/news/home/20210622005425/en/
- View the full release here: https://www.businesswire.com/news/home/20210622005425/en/
Rendering of AbCelleras GMP Facility at 900-Block Evans Avenue. - The 380,000-square-foot headquarters on 4th Avenue between Columbia and Manitoba Streets will be within walking distance of the new GMP manufacturing facility.
- The new GMP facility will be built on what is currently a vacant two-acre site, and the planned building will house laboratory, office, GMP protein biologic manufacturing, and warehouse space.
- The facility is scheduled to be ready for GMP manufacturing in early 2024, and at full capacity will employ hundreds of highly skilled scientific personnel.